Company intelligence / Profile preview

Resilient Pharmaceuticals

Whippany, New Jersey, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Resilient Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of branded and generic products, primarily in the pain management space. The company's lead product was a generic version of the Lidocaine Patch 5%, indicated for the relief of pain associated with post-herpetic neuralgia. In July 2019, the company's assets and operations were acquired by Scilex Holding Company, a subsidiary of Sorrento Therapeutics. This acquisition expanded Scilex's pain management portfolio, complementing its existing topical lidocaine products like ZTlido.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Resilient Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resilient Pharmaceuticals.

Explore the full profile